Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
The vast majority of Americans say what they want at the end of life is to die in their own homes, as comfortable and pain-free as possible. The hospice philosophy is about making sure that a patient's death experience reflects their wishes by supporting one's life to the fullest dignity, regardless how much time remains. In fact, in many cases patients' quality of life can actually improve when they are admitted to hospice at the appropriate time.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
The American Society for Aesthetic Plastic Surgery (ASAPS), is hosting a panel discussion today on the fast-evolving practice of fat grafting, and how surgeons are discovering best practices to produce the most natural looking results. Physician members of ASAPS concur that less is more when it comes to utilizing a patient’s own fat to enhance certain anatomical regions including the breast and buttocks. Further, they agree that fat grafting is proving to be a novel technique for body sculpting previously neglected areas including women’s and men’s shoulders, pectorals, legs and stomachs to create definition.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310752-asaps-plastic-surgery-fat-grafting/
The American Society for Aesthetic Plastic Surgery (ASAPS), is hosting a panel discussion about the latest best practices and uses for injectables including the newest FDA-approved options at The Aesthetic Meeting today in Montreal, Quebec Canada.
The panel discussed the latest advances, including the ways various dermal fillers can be utilized to produce optimal results for targeted areas. There are thirteen FDA-approved dermal fillers on the market to-date, providing aesthetic plastic surgeons with the ability to customize anti-aging treatments to patients’ needs. “The filler choices are dictated by a patient’s unique aging pattern, the anatomical area to be treated and physiochemical properties,” explains ASAPS member, Dr. Z. Paul Lorenc.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310753-asaps-facial-rejuvenation-injectables/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
The Crohn’s & Colitis Foundation of America (CCFA) is collaborating with the University of North Carolina School of Medicine (UNC) to create a research partnership between patients with inflammatory bowel disease (IBD) and the scientific community. CCFA Partners is a “patient-powered research network” for Crohn’s disease and ulcerative colitis (collectively known as IBD) that uses state-of-the-art bioinformatics to engage and gather information from patients that researchers can study and analyze along with clinical and other patient-generated data.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7449851-crohn-s-colitis-foundation-ccfa-ibd/
Following years of trying to expand their family, Lisa and James Park of Raleigh, NC were named the winning family in Ferring Pharmaceuticals’ 2014 Heart to Heart Video Contest. This marks the tenth year Ferring has provided educational grants through patient contests, giving parents who have struggled with infertility the chance to win thousands of dollars for their child’s education by sharing their story.
Lisa and James’ rollercoaster journey to parenthood included multiple rounds of in vitro fertilization (IVF), intrauterine insemination (IUI) and a frozen embryo transfer. They hope that by sharing their story and video, they can help raise awareness about infertility and provide hope for others facing similar struggles. You can view Park family’s full video at www.hearttoheartcontest.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7444651-ferring-pharmaceuticals-heart-to-heart/
On the eve of World Cancer Day 2015, amidst the ongoing cost-of-cancer-care debate, PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, is launching the PACE Continuous Innovation Indicators™ (CII). CII is the first evidence-based, customizable online tool to review progress against cancer over time—initially covering 12 cancer types. The purpose of the tool is to inform public policy reforms and other efforts to accelerate continuous innovation against cancer.
“We have seen tremendous progress in cancer treatment and care during the past decades, and continuous innovation, with one discovery building on another, is responsible for most of it,” said John C. Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer of Eli Lilly and Company (NYSE:LLY). “To keep the momentum going, we need policies that support continuous innovation, but first we need a deeper understanding of the innovations that have occurred, and where we need to be.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7419451-eli-lilly-oncology-pace/
I am a dialysis patient, we lost over 10 people in 3 years at my dialysis clinic so I thought I would make a farewell video to show I enjoyed my life in case I die prematurely
http://yourinnerpower.com.au/ - Shane is a crystal meth addict. He approached Your Inner Power to look for help. Jackie Durnin helped him release his addictive feelings for the substance by using EFT Tapping method. Visit our website!
http://yourinnerpower.com.au/ - Ashley with issues of prescription drug addiction & emotional trauma visited Your Inner Power to seek help. Jackie Durnin dealt her with an EFT Tapping method to bring back compassion in her life. Visit us online!
